

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent of:

HU *et al.*

Patent. No.: 7,153,942 B2

Issued: December 26, 2006

For: **Vascular Endothelial Growth
Factor 2**

Confirmation No.: 3533

Art Unit: 1647

Examiner: Landsman, Robert S.

Atty. Docket: 1488.100000O/PAJ/LMB

Request for Certificate of Correction Under 37 C.F.R. § 1.322

Attn: Certificate of Correction Branch

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

It is hereby requested that a Certificate of Correction under 37 C.F.R. § 1.322 be issued for the above-captioned United States Patent. This Certificate of Correction is being requested due to mistakes which appear in the printed patent. These mistakes were made by the U.S. Patent and Trademark Office.

Specifically, the printed patent contains the following errors for which a Certificate of Correction is respectfully requested:

On the front page, first column, Section (63), please delete "filed on Nov. 21, 1999" and insert therein -- filed on Nov. 12, 1999 --. Support for this correction can be found in the updated Official Filing Receipt mailed on February 21, 2002, a copy of which is enclosed.

In addition, in column 13, line 48 to column 14, line 65, please delete

"Ala(residue 24) -- Ser(residue 419)

Pro(25) -- Ser(419)

Ala(26) -- Ser(419)

Ala(27) -- Ser(419)

Ala(28) -- Ser(419)

Ala(29) -- Ser(419)

Ala(30) -- Ser(419)

Phe(31) -- Ser(419)

Glu(41) -- Ser(419)

Pro(42) -- Ser(419)

Asp(43) -- Ser(419)

Ala(44) -- Ser(419)

Gly(45) -- Ser(419)

Glu(46) -- Ser(419)

Ala(47) -- Ser(419)

Thr(48) -- Ser(419)

Ala(49) -- Ser(419)

Tyr(50) -- Ser(419)

Ser(52) -- Ser(419)

Asp(54) -- Ser(419)

Val(62) -- Ser(419)

Val(65) -- Ser(419)

Met(1), Glu(23), or Ala(24) -- Met(418)

Met(1), Glu(23), or Ala(24) -- Gln(417)

Met(1), Glu(23), or Ala(24) -- Pro(416)

Met(1), Glu(23), or Ala(24) -- Arg(415)

Met(1), Glu(23), or Ala(24) -- Asp(311)

Met(1), Glu(23), or Ala(24) -- Pro(367)

Met(1) -- Ser(419)

Met(1) -- Ser(228)

Glu(47) -- Ser(419)

Ala(111) -- Lys(214)

Ala(112) -- Lys(214)

His(113) -- Lys(214)

Tyr(114) -- Lys(214)

Asn(115) -- Lys(214)

Thr(116) -- Lys(214)

Thr(103) -- Leu(215)

Glu(104) -- Leu(215)

Glu(105) -- Leu(215)

Thr(106) -- Leu(215)

Ile(107) -- Leu(215)

Lys(108) -- Leu(215)

Phe(109) -- Leu(215)

Ala(110) -- Leu(215)

Ala(111) -- Leu(215)

Glu(32) -- Ser(419)

Ser(33) -- Ser(419)

Gly(34) -- Ser(419)

Leu(35) -- Ser(419)

Asp(36) -- Ser(419)

Leu(37) -- (Ser(419)

Ser(38) -- Ser(419)

Asp(39) -- Ser(419)

Ala(40) -- Ser(419)

Met(1), Glu(23), or Ala(24) -- Gln(414)

Met(1), Glu(23), or Ala(24) -- Trp(413)

Met(1), Glu(23), or Ala(24) -- Tyr(412)

Met(1), Glu(23), or Ala(24) -- Ser(411)

Met(1), Glu(23), or Ala(24) -- Pro(410)

Met(1), Glu(23), or Ala(24) -- Val(409)

Met(1), Glu(23), or Ala(24) -- Cys(408)

Met(1), Glu(23), or Ala(24) -- Arg(407)

Met(1), Glu(23), or Ala(24) -- Cys(406)

Met(1), Glu(23), or Ala(24) -- Val(405)

Met(1), Glu(23), or Ala(24) -- Glu(404)

Met(1), Glu(23), or Ala(24) -- Glu(403)

Met(1), Glu(23), or Ala(24) -- Ser(402)

Met(1), Glu(23), or Ala(24) -- Gly(398)

Met(1), Glu(23), or Ala(24) -- Pro(397)

Met(1), Glu(23), or Ala(24) -- Lys(393)

Met(1), Glu(23), or Ala(24) -- Met(263)

Tyr(114) -- Ser(228)

Asn(115) -- Ser(228)

Thr(116) -- Ser(228)

Thr(103) -- Leu(229)

Glu(104) -- Leu(229)

Thr(103) -- Arg(227)

Glu(104) -- Arg(227)

Glu(105) -- Arg(227)

Thr(106) -- Arg(227)

Ile(107) -- Arg(227)

Lys(108) -- Arg(227)

Phe(109) -- Arg(227)

Ala(110) -- Arg(227)

Ala(111) -- Arg(227)

Ala(112) -- Arg(227)

His(113) -- Arg(227)

Tyr(114) -- Arg(227)

Asn(115) -- Arg(227)

Thr(116) -- Arg(227)

Thr(103) -- Ser(213)

Ala(112) -- Leu(215)
His(113) -- Leu(215)
Tyr(114) -- Leu(215)
Asn(115) -- Leu(215)
Thr(116) -- Leu(215)
Thr(103) -- Ser(228)
Glu(104) -- Ser(228)
Glu(105) -- Ser(228)
Thr(106) -- Ser(228)
Ile(107) -- Ser(228)
Lys(108) -- Ser(228)
Phe(109) -- Ser(228)
Ala(110) -- Ser(228)
Ala(111) -- Ser(228)
Ala(112) -- Ser(228)
His(113) -- Ser(228)
Thr(106) -- Lys(214)
Ile(107) -- Lys(214)
Lys(108) -- Lys(214)
Phe(109) -- Lys(214)
Ala(110) -- Lys(214)
Glu(105) -- Leu(229)
Thr(106) -- Leu(229)
Ile(107) -- Leu(229)
Lys(108) -- Leu(229)
Phe(109) -- Leu(229)
Ala(110) -- Leu(229)
Ala(111) -- Leu(229)
Ala(112) -- Leu(229)
His(113) -- Leu(229)
Tyr(114) -- Leu(229)
Asn(115) -- Leu(229)
Thr(116) -- Leu(229)", and insert therein

Glu(104) -- Ser(213)
Glu(105) -- Ser(213)
Thr(106) -- Ser(213)
Ile(107) -- Ser(213)
Lys(108) -- Ser(213)
Phe(109) -- Ser(213)
Ala(110) -- Ser(213)
Ala(111) -- Ser(213)
Ala(112) -- Ser(213)
His(113) -- Ser(213)
Tyr(114) -- Ser(213)
Asn(115) -- Ser(213)
Thr(116) -- Ser(213)
Thr(103) -- Lys(214)
Glu(104) -- Lys(214)
Glu(105) -- Lys(214)

-- Ala(residue 25) -- Ser(residue 419)
Pro(26) -- Ser(419)
Ala(27) -- Ser(419)
Ala(28) -- Ser(419)
Ala(29) -- Ser(419)
Ala(30) -- Ser(419)
Ala(31) -- Ser(419)
Phe(32) -- Ser(419)

Glu(42) -- Ser(419)
Pro(43) -- Ser(419)
Asp(44) -- Ser(419)
Ala(45) -- Ser(419)

Glu(33) -- Ser(419)
Ser(34) -- Ser(419)
Gly(35) -- Ser(419)
Leu(36) -- Ser(419)
Asp(37) -- Ser(419)
Leu(38) -- Ser(419)
Ser(39) -- Ser(419)
Asp(40) -- Ser(419)
Ala(41) -- Ser(419)
Met(1), Glu(24), or Ala(25) -- Gln(414)
Met(1), Glu(24), or Ala(25) -- Trp(413)
Met(1), Glu(24), or Ala(25) -- Tyr(412)
Met(1), Glu(24), or Ala(25) -- Ser(411)

Gly(46) -- Ser(419)
Glu(47) -- Ser(419)
Ala(48) -- Ser(419)
Thr(49) -- Ser(419)
Ala(50) -- Ser(419)
Tyr(51) -- Ser(419)
Ser(53) -- Ser(419)
Asp(55) -- Ser(419)
Val(63) -- Ser(419)
Val(66) -- Ser(419)
Met(1), Glu(24), or Ala(25) -- Met(418)
Met(1), Glu(24), or Ala(25) -- Gln(417)
Met(1), Glu(24), or Ala(25) -- Pro(416)
Met(1), Glu(24), or Ala(25) -- Arg(415)
Met(1), Glu(24), or Ala(25) -- Asp(311)
Met(1), Glu(24), or Ala(25) -- Pro(366)
Met(1) -- Ser(419)
Met(1) -- Ser(228)
Glu(47) -- Ser(419)
Ala(111) -- Lys(214)
Ala(112) -- Lys(214)
His(113) -- Lys(214)
Tyr(114) -- Lys(214)
Asn(115) -- Lys(214)
Thr(116) -- Lys(214)
Thr(103) -- Leu(215)
Glu(104) -- Leu(215)
Glu(105) -- Leu(215)
Thr(106) -- Leu(215)
Ile(107) -- Leu(215)
Lys(108) -- Leu(215)
Phe(109) -- Leu(215)
Ala(110) -- Leu(215)
Ala(111) -- Leu(215)
Ala(112) -- Leu(215)
His(113) -- Leu(215)
Tyr(114) -- Leu(215)
Asn(115) -- Leu(215)
Thr(116) -- Leu(215)
Thr(103) -- Ser(228)
Glu(104) -- Ser(228)
Glu(105) -- Ser(228)
Thr(106) -- Ser(228)
Ile(107) -- Ser(228)
Lys(108) -- Ser(228)
Phe(109) -- Ser(228)
Ala(110) -- Ser(228)

Met(1), Glu(24), or Ala(25) -- Pro(410)
Met(1), Glu(24), or Ala(25) -- Val(409)
Met(1), Glu(24), or Ala(25) -- Cys(408)
Met(1), Glu(24), or Ala(25) -- Arg(407)
Met(1), Glu(24), or Ala(25) -- Cys(406)
Met(1), Glu(24), or Ala(25) -- Val(405)
Met(1), Gly(24), or Ala(25) -- Glu(404)
Met(1), Glu(24), or Ala(25) -- Glu(403)
Met(1), Glu(24), or Ala(25) -- Ser(402)
Met(1), Glu(24), or Ala(25) -- Gly(398)
Met(1), Glu(24), or Ala(25) -- Pro(397)
Met(1), Glu(24), or Ala(25) -- Lys(393)
Met(1), Glu(24), or Ala(25) -- Met(263)

Tyr(114) -- Ser(228)
Asn(115) -- Ser(228)
Thr(116) -- Ser(228)
Thr(103) -- Leu(229)
Glu(104) -- Leu(229)
Thr(103) -- Arg(227)
Glu(104) -- Arg(227)
Glu(105) -- Arg(227)
Thr(106) -- Arg(227)
Ile(107) -- Arg(227)
Lys(108) -- Arg(227)
Phe(109) -- Arg(227)
Ala(110) -- Arg(227)
Ala(111) -- Arg(227)
Ala(112) -- Arg(227)
His(113) -- Arg(227)
Tyr(114) -- Arg(227)
Asn(115) -- Arg(227)
Thr(116) -- Arg(227)
Thr(103) -- Ser(213)
Glu(104) -- Ser(213)
Glu(105) -- Ser(213)
Thr(106) -- Ser(213)
Ile(107) -- Ser(213)
Lys(108) -- Ser(213)
Phe(109) -- Ser(213)
Ala(110) -- Ser(213)
Ala(111) -- Ser(213)
Ala(112) -- Ser(213)
His(113) -- Ser(213)
Tyr(114) -- Ser(213)
Asn(115) -- Ser(213)
Thr(116) -- Ser(213)

Ala(111) -- Ser(228)
Ala(112) -- Ser(228)
His(113) -- Ser(228)
Thr(106) -- Lys(214)
Ile(107) -- Lys(214)
Lys(108) -- Lys(214)
Phe(109) -- Lys(214)
Ala(110) -- Lys(214)
Glu(105) -- Leu(229)
Thr(106) -- Leu(229)
Ile(107) -- Leu(229)
Lys(108) -- Leu(229)
Phe(109) -- Leu(229)
Ala(110) -- Leu(229)
Ala(111) -- Leu(229)
Ala(112) -- Leu(229)
His(113) -- Leu(229)
Tyr(114) -- Leu(229)
Asn(115) -- Leu(229)
Thr(116) -- Leu(229) -- .

Thr(103) -- Lys(214)
Glu(104) -- Lys(214)
Glu(105) -- Lys(214)

Support for this correction can be found in the Preliminary Amendment filed on
April 12, 2006, a copy of which is enclosed.

Remarks

The above-noted corrections do not involve such changes in the patent as would constitute new matter or would require reexamination.

A completed Form PTO/SB/44 accompanies this request, with the above-noted corrections printed thereon. Accordingly, a Certificate of Correction is believed proper and issuance thereof is respectfully requested. No fee is required because this was a mistake of the USPTO.

The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Lori M. Brandes
Agent for Patentees
Registration No. 57,772

Date: 3/27/07

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
648771

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 4

PATENT NO: 7,153,942 B2

DATED: December 26, 2006

INVENTOR(S): HU *et al.*

It is certified that error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below.

On the front page, first column, Section (63), please delete "filed on Nov. 21, 1999"
and insert therein -- filed on Nov. 12, 1999 --.

In column 13, line 48 to column 14, line 65, please delete

"Ala(residue 24) -- Ser(residue 419)	Glu(32) -- Ser(419)
Pro(25) -- Ser(419)	Ser(33) -- Ser(419)
Ala(26) -- Ser(419)	Gly(34) -- Ser(419)
Ala(27) -- Ser(419)	Leu(35) -- Ser(419)
Ala(28) -- Ser(419)	Asp(36) -- Ser(419)
Ala(29) -- Ser(419)	Leu(37) -- (Ser(419)
Ala(30) -- Ser(419)	Ser(38) -- Ser(419)
Phe(31) -- Ser(419)	Asp(39) -- Ser(419)
	Ala(40) -- Ser(419)
Glu(41) -- Ser(419)	Met(1), Glu(23), or Ala(24) -- Gln(414)
Pro(42) -- Ser(419)	Met(1), Glu(23), or Ala(24) -- Trp(413)
Asp(43) -- Ser(419)	Met(1), Glu(23), or Ala(24) -- Tyr(412)
Ala(44) -- Ser(419)	Met(1), Glu(23), or Ala(24) -- Ser(411)
Gly(45) -- Ser(419)	Met(1), Glu(23), or Ala(24) -- Pro(410)
Glu(46) -- Ser(419)	Met(1), Glu(23), or Ala(24) -- Val(409)
Ala(47) -- Ser(419)	Met(1), Glu(23), or Ala(24) -- Cys(408)
Thr(48) -- Ser(419)	Met(1), Glu(23), or Ala(24) -- Arg(407)
Ala(49) -- Ser(419)	Met(1), Glu(23), or Ala(24) -- Cys(406)
Tyr(50) -- Ser(419)	Met(1), Glu(23), or Ala(24) -- Val(405)
Ser(52) -- Ser(419)	Met(1), Glu(23), or Ala(24) -- Glu(404)
Asp(54) -- Ser(419)	Met(1), Glu(23), or Ala(24) -- Glu(403)
Val(62) -- Ser(419)	Met(1), Glu(23), or Ala(24) -- Ser(402)
Val(65) -- Ser(419)	Met(1), Glu(23), or Ala(24) -- Gly(398)
Met(1), Glu(23), or Ala(24) -- Met(418)	Met(1), Glu(23), or Ala(24) -- Pro(397)
Met(1), Glu(23), or Ala(24) -- Gln(417)	Met(1), Glu(23), or Ala(24) -- Lys(393)

MAILING ADDRESS OF SENDER (Please do not use customer number below):

1100 New York Avenue, NW

Washington DC 20005-3934

Atty. Dkt. No. 1488.100000O/PAJ/LMB

This collection of information is required by 37 CFR 1.322, 1.323 and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Met(1), Glu(23), or Ala(24) -- Pro(416)
 Met(1), Glu(23), or Ala(24) -- Arg(415)
 Met(1), Glu(23), or Ala(24) -- Asp(311)
 Met(1), Glu(23), or Ala(24) -- Pro(367)
 Met(1) -- Ser(419)
 Met(1) -- Ser(228)
 Glu(47) -- Ser(419)
 Ala(111) -- Lys(214)
 Ala(112) -- Lys(214)
 His(113) -- Lys(214)
 Tyr(114) -- Lys(214)
 Asn(115) -- Lys(214)
 Thr(116) -- Lys(214)
 Thr(103) -- Leu(215)
 Glu(104) -- Leu(215)
 Glu(105) -- Leu(215)
 Thr(106) -- Leu(215)
 Ile(107) -- Leu(215)
 Lys(108) -- Leu(215)
 Phe(109) -- Leu(215)
 Ala(110) -- Leu(215)
 Ala(111) -- Leu(215)
 Ala(112) -- Leu(215)
 His(113) -- Leu(215)
 Tyr(114) -- Leu(215)
 Asn(115) -- Leu(215)
 Thr(116) -- Leu(215)
 Thr(103) -- Ser(228)
 Glu(104) -- Ser(228)
 Glu(105) -- Ser(228)
 Thr(106) -- Ser(228)
 Ile(107) -- Ser(228)
 Lys(108) -- Ser(228)
 Phe(109) -- Ser(228)
 Ala(110) -- Ser(228)
 Ala(111) -- Ser(228)
 Ala(112) -- Ser(228)
 His(113) -- Ser(228)
 Thr(106) -- Lys(214)
 Ile(107) -- Lys(214)
 Lys(108) -- Lys(214)
 Phe(109) -- Lys(214)
 Ala(110) -- Lys(214)
 Glu(105) -- Leu(229)
 Thr(106) -- Leu(229)

Met(1), Glu(23), or Ala(24) -- Met(263)

Tyr(114) -- Ser(228)
 Asn(115) -- Ser(228)
 Thr(116) -- Ser(228)
 Thr(103) -- Leu(229)
 Glu(104) -- Leu(229)
 Thr(103) -- Arg(227)
 Glu(104) -- Arg(227)
 Glu(105) -- Arg(227)
 Thr(106) -- Arg(227)
 Ile(107) -- Arg(227)
 Lys(108) -- Arg(227)
 Phe(109) -- Arg(227)
 Ala(110) -- Arg(227)
 Ala(111) -- Arg(227)
 Ala(112) -- Arg(227)
 His(113) -- Arg(227)
 Tyr(114) -- Arg(227)
 Asn(115) -- Arg(227)
 Thr(116) -- Arg(227)
 Thr(103) -- Ser(213)
 Glu(104) -- Ser(213)
 Glu(105) -- Ser(213)
 Thr(106) -- Ser(213)
 Ile(107) -- Ser(213)
 Lys(108) -- Ser(213)
 Phe(109) -- Ser(213)
 Ala(110) -- Ser(213)
 Ala(111) -- Ser(213)
 Ala(112) -- Ser(213)
 His(113) -- Ser(213)
 Tyr(114) -- Ser(213)
 Asn(115) -- Ser(213)
 Thr(116) -- Ser(213)
 Thr(103) -- Lys(214)
 Glu(104) -- Lys(214)
 Glu(105) -- Lys(214)

MAILING ADDRESS OF SENDER (Please do not use customer number below):

1100 New York Avenue, NW

Washington DC 20005-3934

Atty. Dkt. No. 1488.100000O/PAJ/LMB

This collection of information is required by 37 CFR 1.322, 1.323 and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Ile(107) -- Leu(229)
 Lys(108) -- Leu(229)
 Phe(109) -- Leu(229)
 Ala(110) -- Leu(229)
 Ala(111) -- Leu(229)
 Ala(112) -- Leu(229)
 His(113) -- Leu(229)
 Tyr(114) -- Leu(229)
 Asn(115) -- Leu(229)
 Thr(116) -- Leu(229)" and insert therein

-- Ala(residue 25) -- Ser(residue 419)

Pro(26) -- Ser(419)
 Ala(27) -- Ser(419)
 Ala(28) -- Ser(419)
 Ala(29) -- Ser(419)
 Ala(30) -- Ser(419)
 Ala(31) -- Ser(419)
 Phe(32) -- Ser(419)

Glu(42) -- Ser(419)

Pro(43) -- Ser(419)

Asp(44) -- Ser(419)

Ala(45) -- Ser(419)

Gly(46) -- Ser(419)

Glu(47) -- Ser(419)

Ala(48) -- Ser(419)

Thr(49) -- Ser(419)

Ala(50) -- Ser(419)

Tyr(51) -- Ser(419)

Ser(53) -- Ser(419)

Asp(55) -- Ser(419)

Val(63) -- Ser(419)

Val(66) -- Ser(419)

Met(1), Glu(24), or Ala(25) -- Met(418)

Met(1), Glu(24), or Ala(25) -- Gln(417)

Met(1), Glu(24), or Ala(25) -- Pro(416)

Met(1), Glu(24), or Ala(25) -- Arg(415)

Met(1), Glu(24), or Ala(25) -- Asp(311)

Met(1), Glu(24), or Ala(25) -- Pro(366)

Met(1) -- Ser(419)

Met(1) -- Ser(228)

Glu(47) -- Ser(419)

Ala(111) -- Lys(214)

Ala(112) -- Lys(214)

Glu(33) -- Ser(419)

Ser(34) -- Ser(419)

Gly(35) -- Ser(419)

Leu(36) -- Ser(419)

Asp(37) -- Ser(419)

Leu(38) -- Ser(419)

Ser(39) -- Ser(419)

Asp(40) -- Ser(419)

Ala(41) -- Ser(419)

Met(1), Glu(24), or Ala(25) -- Gln(414)

Met(1), Glu(24), or Ala(25) -- Trp(413)

Met(1), Glu(24), or Ala(25) -- Tyr(412)

Met(1), Glu(24), or Ala(25) -- Ser(411)

Met(1), Glu(24), or Ala(25) -- Pro(410)

Met(1), Glu(24), or Ala(25) -- Val(409)

Met(1), Glu(24), or Ala(25) -- Cys(408)

Met(1), Glu(24), or Ala(25) -- Arg(407)

Met(1), Glu(24), or Ala(25) -- Cys(406)

Met(1), Glu(24), or Ala(25) -- Val(405)

Met(1), Gly(24), or Ala(25) -- Glu(404)

Met(1), Glu(24), or Ala(25) -- Glu(403)

Met(1), Glu(24), or Ala(25) -- Ser(402)

Met(1), Glu(24), or Ala(25) -- Gly(398)

Met(1), Glu(24), or Ala(25) -- Pro(397)

Met(1), Glu(24), or Ala(25) -- Lys(393)

Met(1), Glu(24), or Ala(25) -- Met(263)

Tyr(114) -- Ser(228)

Asn(115) -- Ser(228)

Thr(116) -- Ser(228)

Thr(103) -- Leu(229)

Glu(104) -- Leu(229)

Thr(103) -- Arg(227)

Glu(104) -- Arg(227)

MAILING ADDRESS OF SENDER (Please do not use customer number below):

1100 New York Avenue, NW

Washington DC 20005-3934

Atty. Dkt. No. 1488.100000O/PAJ/LMB

This collection of information is required by 37 CFR 1.322, 1.323 and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

His(113) -- Lys(214)	Glu(105) -- Arg(227)
Tyr(114) -- Lys(214)	Thr(106) -- Arg(227)
Asn(115) -- Lys(214)	Ile(107) -- Arg(227)
Thr(116) -- Lys(214)	Lys(108) -- Arg(227)
Thr(103) -- Leu(215)	Phe(109) -- Arg(227)
Glu(104) -- Leu(215)	Ala(110) -- Arg(227)
Glu(105) -- Leu(215)	Ala(111) -- Arg(227)
Thr(106) -- Leu(215)	Ala(112) -- Arg(227)
Ile(107) -- Leu(215)	His(113) -- Arg(227)
Lys(108) -- Leu(215)	Tyr(114) -- Arg(227)
Phe(109) -- Leu(215)	Asn(115) -- Arg(227)
Ala(110) -- Leu(215)	Thr(116) -- Arg(227)
Ala(111) -- Leu(215)	Thr(103) -- Ser(213)
Ala(112) -- Leu(215)	Glu(104) -- Ser(213)
His(113) -- Leu(215)	Glu(105) -- Ser(213)
Tyr(114) -- Leu(215)	Thr(106) -- Ser(213)
Asn(115) -- Leu(215)	Ile(107) -- Ser(213)
Thr(116) -- Leu(215)	Lys(108) -- Ser(213)
Thr(103) -- Ser(228)	Phe(109) -- Ser(213)
Glu(104) -- Ser(228)	Ala(110) -- Ser(213)
Glu(105) -- Ser(228)	Ala(111) -- Ser(213)
Thr(106) -- Ser(228)	Ala(112) -- Ser(213)
Ile(107) -- Ser(228)	His(113) -- Ser(213)
Lys(108) -- Ser(228)	Tyr(114) -- Ser(213)
Phe(109) -- Ser(228)	Asn(115) -- Ser(213)
Ala(110) -- Ser(228)	Thr(116) -- Ser(213)
Ala(111) -- Ser(228)	Thr(103) -- Lys(214)
Ala(112) -- Ser(228)	Glu(104) -- Lys(214)
His(113) -- Ser(228)	Glu(105) -- Lys(214)
Thr(106) -- Lys(214)	
Ile(107) -- Lys(214)	
Lys(108) -- Lys(214)	
Phe(109) -- Lys(214)	
Ala(110) -- Lys(214)	
Glu(105) -- Leu(229)	
Thr(106) -- Leu(229)	
Ile(107) -- Leu(229)	
Lys(108) -- Leu(229)	
Phe(109) -- Leu(229)	
Ala(110) -- Leu(229)	
Ala(111) -- Leu(229)	
Ala(112) -- Leu(229)	
His(113) -- Leu(229)	
Tyr(114) -- Leu(229)	
Asn(115) -- Leu(229)	
Thr(116) -- Leu(229) -- .	

MAILING ADDRESS OF SENDER (Please do not use customer number below):

1100 New York Avenue, NW
Washington DC 20005-3934

Atty. Dkt. No. 1488.1000000/PAJ/LMB

This collection of information is required by 37 CFR 1.322, 1.323 and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/935,726	08/24/2001	1647	2438	PF112P3D1C1	47	76	12

CONFIRMATION NO. 3533

22195
HUMAN GENOME SCIENCES INC
9410 KEY WEST AVENUE
ROCKVILLE, MD 20850

RECEIVED

UPDATED FILING RECEIPT



OC000000007512925

FEB 28 2002
MMAW AKR
HQS PATENT DEPT

Date Mailed: 02/21/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

Jing-Shan Hu, Sunnyvale, CA;
Craig A. Rosen, Laytonsville, MD;
Liang Cao, South Horizons, HONG KONG;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF 09/438,538 11/12/1999 ABN
WHICH IS A DIV OF 09/042,105 03/13/1998 PAT 6,040,157
WHICH IS A CIP OF 08/999,811 12/24/1997 PAT 5,932,540
WHICH IS A CIP OF 08/465,968 06/06/1995
WHICH IS A CIP OF 08/824,996 03/27/1997 PAT 5,935,820
WHICH IS A DIV OF 08/207,550 03/08/1994 ABN

Foreign Applications

If Required, Foreign Filing License Granted 12/04/2001

Projected Publication Date: 05/30/2002

Non-Publication Request: No

Early Publication Request: No

Title

Vascular endothelial growth factor 2

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Hu *et al.*

Appl. No.: 09/935,726

Filed: August 24, 2001

For: **Vascular Endothelial Growth
Factor 2**

Confirmation No.: 3533

Art Unit: 1647

Examiner: Landsman, Robert S.

Atty. Docket: 1488.100000O/HCC/LMB

Preliminary Amendment Under 37 C.F.R. § 1.115

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In advance of prosecution, Applicants submit the following amendments and remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments to the Specification begin on page 2 of this paper.

Remarks begin on page 9 of this paper.

Amendments to the Specification

Please replace the paragraph on page 1 that begins on line 3 with the following amended paragraph:

This application is a continuation of U.S. Application No. 09/438,538, filed November 12, 1999 (now abandoned), which is a division of U.S. Application No. 09/042,105, filed March 13, 1998 (now U.S. Patent No. 6,040,157, issued on March 21, 2000), which is a continuation-in-part of U.S. Application No. 08/999,811, filed December 24, 1997 (now issued U.S. Patent No. 5,932,540), which is a continuation-in-part of both U.S. ~~Applications~~ Serial Application No. 08/465,968, filed June 6, 1995 (now issued U.S. Patent No. 6,608,182), and ~~Serial~~ U.S. Application No. 08/207,550, (now abandoned), said 08/465,968 is a continuation-in-part of U.S. Application ~~Serial~~ No. 08/207,550, filed March 8, 1994 (now abandoned), all of which claim priority under 35 U.S.C. § 120, and all are hereby incorporated by reference in their entirety.

Please replace the paragraph on page 8 that begins on line 19 with the following amended paragraph:

FIGs. ~~26A-G depicts~~ 26A-26G depict the ability of VEGF2 to affect the diastolic blood pressure in spontaneously hypertensive rats (SHR). FIGs. 26a and b depict the dose-dependent decrease in diastolic blood pressure achieved with VEGF2. (FIGs. 26c and d depict the decreased mean arterial pressure (MAP) observed with VEGF2. For

FIGs. 26E-G, increasing doses of VEGF-2 (HG00403-B8, HG00404-C5, and HG00404-C4) were administered to 13-14 week old SHR and the data are expressed as the mean +/- SEM. Statistical analysis were performed with a paired t-test and significance was defined as $p < 0.05$ vs. the response buffer alone. Panel E shows the effect of increasing doses of VEGF-2 on the mean arterial pressure (MAP) of SHR rats. The response to B8 and C4 were significant at the 300 $\mu\text{g/kg}$ dose. The response to C5 was significant at the 100, 300 and 900 $\mu\text{g/kg}$ doses. Panel F shows the effect of VEGF-2 on the diastolic blood pressure of SHR rats. The response to B8 was significant at the 300 $\mu\text{g/kg}$ dose. Administration of C5 yielded significant responses at doses greater than or equal to 100 $\mu\text{g/kg}$. The response to C4 was significant when 10, 100, 300 and 900 $\mu\text{g/kg}$ were given. Panel G shows the effect of VEGF-2 on the diastolic blood pressure of SHR rats. The response to B8 was significant only at the 300 $\mu\text{g/kg}$ dose and when given acetylcholine. The responses to C4 and C5, while much less dramatic, were statistically significant at all dose levels.

Please replace the paragraph on page 9 that begins on line 8 with the following amended paragraph:

In accordance with one aspect of the present invention, there are provided isolated nucleic acid molecules comprising a polynucleotide encoding a VEGF2 polypeptide having the deduced amino acid sequence of Figure 1 (SEQ ID NO:2), which was determined by sequencing a cloned cDNA. The nucleotide sequence shown in SEQ ID NO:1 was obtained by sequencing a cDNA clone, which was deposited on May 12,

1995 at the ~~American Type Tissue Collection (ATCC), 12301 Park Lawn Drive, Rockville, Maryland 20852,~~ American Type Culture Collection (ATCC), Patent Depository, 10801 University Boulevard, Manassas, VA 20110, and given ATCC Deposit No. 97149.

Please replace the paragraph on page 9 that begins on line 16 with the following amended paragraph:

In accordance with another aspect of the present invention, there are provided isolated nucleic acid molecules comprising a polynucleotide encoding a truncated VEGF2 polypeptide having the deduced amino acid sequence of Figure 2 (SEQ ID NO:4), which was determined by sequencing a cloned cDNA. The nucleotide sequence shown in SEQ ID NO:3 was obtained by sequencing a cDNA clone, which was deposited on March 4, 1994 at the ~~American Type Tissue Collection (ATCC), 12301 Park Lawn Drive, Rockville, Maryland 20852,~~ American Type Culture Collection (ATCC), Patent Depository, 10801 University Boulevard, Manassas, VA 20110, and given ATCC Deposit Number 75698.

Please replace the paragraph beginning at page 22, line 6 with the following amended paragraph:

Particularly preferred VEGF-2 polypeptides are shown below (numbering starts with the first amino acid in the protein (Met) (Figure 1 (SEQ ID NO:18)):

Ala (residue <u>24 25</u>) -- Ser (residue 419)	Glu (<u>32 33</u>) -- Ser (419)
Pro (<u>25 26</u>) -- Ser (419)	Ser (<u>33 34</u>) -- Ser (419)
Ala (<u>26 27</u>) -- Ser (419)	Gly (<u>34 35</u>) -- Ser (419)
Ala (<u>27 28</u>) -- Ser (419)	Leu (<u>35 36</u>) -- Ser (419)
Ala (<u>28 29</u>) -- Ser (419)	Asp (<u>36 37</u>) -- Ser (419)
Ala (<u>29 30</u>) -- Ser (419)	Leu (<u>37 38</u>) -- (Ser (419)
Ala (<u>30 31</u>) -- Ser (419)	Ser (<u>38 39</u>) -- Ser (419)
Phe (<u>31 32</u>) -- Ser (419)	Asp (<u>39 40</u>) -- Ser (419)
	Ala (<u>40 41</u>) -- Ser (419)
Glu (<u>41 42</u>) -- Ser (419)	Met(1), Glu (<u>23 24</u>), or Ala (<u>24 25</u>) -- Gln (414)
Pro (<u>42 43</u>) -- Ser (419)	Met(1), Glu (<u>23 24</u>), or Ala (<u>24 25</u>) -- Trp (413)
Asp (<u>43 44</u>) -- Ser (419)	Met(1), Glu (<u>23 24</u>), or Ala (<u>24 25</u>) -- Tyr (412)
Ala ([[44]] <u>45</u>) -- Ser (419)	Met(1), Glu (<u>23 24</u>), or Ala (<u>24 25</u>) -- Ser (411)
Gly (<u>45 46</u>) -- Ser (419)	Met(1), Glu (<u>23 24</u>), or Ala (<u>24 25</u>) -- Pro (410)
Glu (<u>46 47</u>) -- Ser (419)	Met(1), Glu (<u>23 24</u>), or Ala (<u>24 25</u>) -- Val (409)
Ala (<u>47 48</u>) -- Ser (419)	Met (1), Glu (<u>23 24</u>), or Ala (<u>24 25</u>) -- Cys (408)
Thr (<u>48 49</u>) -- Ser (419)	Met (1), Glu (<u>23 24</u>), or Ala (<u>24 25</u>) -- Arg (407)
Ala (<u>49 50</u>) -- Ser (419)	Met(1), Glu (<u>23 24</u>), or Ala (<u>24 25</u>) -- Cys (406)
Tyr (<u>50 51</u>) -- Ser (419)	Met(1), Glu (<u>23 24</u>), or Ala (<u>24 25</u>) -- Val (405)
Ser (<u>52 53</u>) -- Ser (419)	Met(1), Gly (<u>23 24</u>), or Ala (<u>24 25</u>) -- Glu (404)
Asp (<u>54 55</u>) -- Ser (419)	Met(1), Glu (<u>23 24</u>), or Ala (<u>24 25</u>) -- Glu (403)
Val (<u>62 63</u>) -- Ser (419)	Met(1), Glu (<u>23 24</u>), or Ala (<u>24 25</u>) -- Ser (402)
Val (<u>65 66</u>) -- Ser (419)	Met(1), Glu (<u>23 24</u>), or Ala (<u>24 25</u>) -- Gly (398)
Met(1), Glu (<u>23 24</u>), or Ala (<u>24 25</u>) -- Met (418)	Met(1), Glu (<u>23 24</u>), or Ala (<u>24 25</u>) -- Pro (397)
Met(1), Glu (<u>23 24</u>), or Ala (<u>24 25</u>) -- Gln (417)	Met(1), Glu (<u>23 24</u>), or Ala (<u>24 25</u>) -- Lys (393)
Met(1), Glu (<u>23 24</u>), or Ala (<u>24 25</u>) -- Pro (416)	Met(1), Glu (<u>23 24</u>), or Ala (<u>24 25</u>) -- Met(263)
Met(1), Glu (<u>23 24</u>), or Ala (<u>24 25</u>) -- Arg (415)	

Met(1), Glu (23 24), or Ala (24 25) -- Asp(311)	Tyr(114) -- Ser(228)
Met(1), Glu (23 24), or Ala (24 25) -- Pro (367 366)	Asn(115) -- Ser(228)
Met(1) -- Ser (419)	Thr(116) -- Ser(228)
Met(1) -- Ser(228)	Thr(103) -- Leu(229)
Glu(47) -- Ser(419)	Glu(104) -- Leu(229)
Ala(111) -- Lys(214)	Thr(103) -- Arg(227)
Ala(112) -- Lys(214)	Glu(104) -- Arg(227)
His(113) -- Lys(214)	Glu(105) -- Arg(227)
Tyr(114) -- Lys(214)	Thr(106) -- Arg(227)
Asn(115) -- Lys(214)	Ile(107) -- Arg(227)
Thr(116) -- Lys(214)	Lys(108) -- Arg(227)
Thr(103) -- Leu(215)	Phe(109) -- Arg(227)
Glu(104) -- Leu(215)	Ala(110) -- Arg(227)
Glu(105) -- Leu(215)	Ala(111) -- Arg(227)
Thr(106) -- Leu(215)	Ala(112) -- Arg(227)
Ile(107) -- Leu(215)	His(113) -- Arg(227)
Lys(108) -- Leu(215)	Tyr(114) -- Arg(227)
Phe(109) -- Leu(215)	Asn(115) -- Arg(227)
Ala(110) -- Leu(215)	Thr(116) -- Arg(227)
Ala(111) -- Leu(215)	Thr(103) -- Ser(213)
Ala(112) -- Leu(215)	Glu(104) -- Ser(213)
His(113) -- Leu(215)	Glu(105) -- Ser(213)
Tyr(114) -- Leu(215)	Thr(106) -- Ser(213)
Asn(115) -- Leu(215)	Ile(107) -- Ser(213)
Thr(116) -- Leu(215)	Lys(108) -- Ser(213)
Thr(103) -- Ser(228)	Phe(109) -- Ser(213)
Glu(104) -- Ser(228)	Ala(110) -- Ser(213)
Glu(105) -- Ser(228)	Ala(111) -- Ser(213)

Thr(106) -- Ser(228)	Ala(112) -- Ser(213)
Ile(107) -- Ser(228)	His(113) -- Ser(213)
Lys(108) -- Ser(228)	Tyr(114) -- Ser(213)
Phe(109) -- Ser(228)	Asn(115) -- Ser(213)
Ala(110) -- Ser(228)	Thr(116) -- Ser(213)
Ala(111) -- Ser(228)	Thr(103) -- Lys(214)
Ala(112) -- Ser(228)	Glu(104) -- Lys(214)
His(113) -- Ser(228)	Glu(105) -- Lys(214)
Thr(106) -- Lys(214)	
Ile(107) -- Lys(214)	
Lys(108) -- Lys(214)	
Phe(109) -- Lys(214)	
Ala(110) -- Lys(214)	
Glu(105) -- Leu(229)	
Thr(106) -- Leu(229)	
Ile(107) -- Leu(229)	
Lys(108) -- Leu(229)	
Phe(109) -- Leu(229)	
Ala(110) -- Leu(229)	
Ala(111) -- Leu(229)	
Ala(112) -- Leu(229)	
His(113) -- Leu(229)	
Tyr(114) -- Leu(229)	
Asn(115) -- Leu(229)	
Thr(116) -- Leu(229)	

Please replace the paragraph on page 24 that begins on line 18 with the following amended paragraph:

Preferred embodiments include the following deletion mutants: Thr(103) -- Arg(227); Glu(104) -- Arg(227); Ala(112) -- Arg(227); Thr(103) -- Ser(213); Glu(104) -- Ser(213); Thr(103) -- Leu(215); Glu(47) -- Ser(419); Met(1), Glu(~~23~~ 24), or Ala(24 25) -- Met(263); Met(1), Glu(~~23~~ 24), or Ala(24 25) -- Asp(311); Met(1), Glu (~~23~~ 24), or Ala(24 25) -- Pro (~~367~~ 366); Met(1) -- Ser(419); and Met(1) -- Ser(228) of (Figure 1 (SEQ ID NO:18)).

Remarks

In the specification, the paragraph on page 1 that begins on line 3 has been amended to reflect the current status of the applications in the priority claim. The paragraph on page 8 that begins on line 19 has been amended to match Figures 26A-26G. The paragraph on page 9 that begins on line 8 and the paragraph on page 9 that begins on line 16 have been amended to reflect the correct title of the American Tissue Culture Collection and its current address. The residue numbering at the paragraph on page 22 that begins on line 6 and the paragraph on page 24 that begins on line 18 has been amended to match Figure 1 and SEQ ID NO:18. Accordingly, these changes are supported by the specification as filed, and thus, no new matter has been added.

Conclusion

Prompt and favorable consideration of this Preliminary Amendment is respectfully requested. Applicants believe the present application is in condition for allowance. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Helene C. Carlson
Agent for Applicants
Registration No. 47,473

Date: 4/12/06

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

514832v1



Robert Greene Sterne
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
John M. Covert
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr.
Michael V. Messinger
Judith U. Kim
Jeffrey T. Helvey

Eldora L. Ellison
Donald R. Banowitz
Peter A. Jackman
Brian J. Del Buono
Mark Fox Evens
Vincent L. Capuano
Elizabeth J. Haanes
Michael D. Specht
Kevin W. McCabe
Edward W. Yee
Virgil Lee Beaton
Theodore A. Wood
Joseph S. Ostroff
Jason D. Eisenberg
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis

Ann E. Summerfield
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gabby L. Longworth
Lori A. Gordon
Laura A. Vogel
Bryan S. Wade
Bashir M.S. Ali
Shannon A. Carroll
Anbar F. Khal
Michelle K. Holoubek
Marsha A. Rose
Scott A. Schaller
Lei Zhou
Young Tang
Christopher J. Walsh

W. Blake Coblenz*
James J. Pohl
John T. Haran
Mark W. Rygiel
Michael R. Malek*
Carla Ji-Eun Kim
Doyle A. Siever*
Alexandra K. Pechhold
C. Matthew Rozier*
Robert A. Schwartzman
Bryan L. Skelton*
Ulrike Winkler

Registered Patent Agents*
Karen R. Markowicz
Matthew J. Dowd
Katrina Yujian Pei Quach
Julie A. Heider

Mita Mukherjee
Scott M. Woodhouse
Peter A. Socarras
Jeffrey K. Mills
Danielle L. Letting
Lori Brandes
Steven C. Oppenheimer
Aaron S. Lukas
Gaurav Asthana

Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
•Practice Limited to Federal Agencies

March 27, 2007

WRITER'S DIRECT NUMBER:
(202) 772-8836
INTERNET ADDRESS:
LBRADES@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Attn: Certificate of Correction Branch

Re: U.S. Patent No. 7,153,942 B2; Issued: December 26, 2006
For: **Vascular Endothelial Growth Factor 2**
Patentees: HU *et al.*
Our Ref: 1488.100000O/PAJ/LMB

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Request for Certificate of Correction Under 37 C.F.R. § 1.322;
2. United States Patent and Trademark Office Certificate of Correction (Form PTO/SB/44);
3. Copy of the Official Filing Receipt mailed February 21, 2002; and
4. Copy of the Preliminary Amendment filed on April 12, 2006.

The above-listed documents are filed electronically through EFS-Web.

Commissioner for Patents
March 27, 2007
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, reading "Lori M. Brandes". The signature is fluid and cursive, with the first letters of each word being capitalized and prominent.

Lori M. Brandes
Agent for Patentees
Registration No. 57,772

PAJ/LMB/eaf
Enclosures

656279v1